TEAM


Richel:Founder & CEO
Richel is Founder and CEO of Rimonci Capital. She is responsible for Rimonci overall strategies and transactions control. Prior to founding Rimonci at start of 2016, Richel served as CEO of a comprehensive IT group in China with 1.5 billion USD in sales, and also Executive Director of HK listed company and chairman of Shanghai listed company in this group. During her tenure, Riche was responsible for different business investment and operation, especially electronics, IC substrate, enterprise software, system integration and finally the overall management of the whole group. With more than 17 years of investment, mergers and acquisitions, business operation and management experience, she has distinguished tracking record on setting up new business and grow business from earlier stage to mature stage either by organic growth or through investment. Richel also have abundant cross-board working experience, competent for multiple board governance structure and management. Richel earned MS degree in economics and BS degree in engineering, also Received Senior Leadership Training Certification from Yale School of Management. Having the qualifications for securities and funds in China.

Eddie:Co-Founder & COO
Eddie is mainly responsible for the deal sourcing, due diligence and operations in Rimonci, and he is also highly involved in the post investment management process to help the portfolio companies to develop in China. Prior to Rimonci, Eddie has already been working in investment industry for years. His personal career started from the financial investment area, where he was focused on the investment as well as fundraising in one of the top private equity investment company in China. After that, Eddie switched to strategic investment and worked as the general manager of the group strategic investment department in one of the Chinese comprehensive IT group, mainly in charge of the group investment, M&A and overseas business development. Eddie has both the B.S in Economics and MBA degrees from Tsinghua University, and also MBA from Hebrew University. He is fluent in English and has rich oversea life experience. During the college, Eddie used to study and work in Korea, India, Uganda, Kenya, and Dubai for years, which helped him to build up the skills for cross culture communications.

Rina:Partner & BD VP
Rina is partner & BD VP of Rimonci, she is responsible for BD development, post- investment management and public relationships. Prior to joining Rimonci, she used to work for the Embassy of Israel as senior trade officer for 6 years. She helped Israeli companies in the investmentICT and homeland security industry to develop their businesses in China, and also helped distinguished Chinese companies find innovative technology and M&A opportunities in Israel. She did great bridge job for government officials, entrepreneurs and senior executives both from China and Israel.  Before working for embassy, she worked for Alcatel-Lucent and Intel in business development for more than 10 years.  Rina is passionate, responsible and considerate.  She has an MBA from Cardiff UniversityUnited Kingdom. Rina is very fluent at English and having the qualifications for securities and funds in China.

Weiwei:CFO
Wei Wei, CPA, CTA and senior florist, is in charge of finance and compliance management in Rimonci. Wei has accumulated rich experience in strategic advisory and corporate finance during her service as assistant manager in KPMG, senior strategy manager and executive assistant to CEO of a multi-billion-dollar-asset company, and financial director in a comprehensive finance group. Wei has an MBA from IESE Business School and double-bachelor in Financial Management and English from Tianjin University. She has advanced professional proficiency in English, and business proficiency in Spanish and Korean. 

ADVISORY BOD


Michael Belkin
Prof. Belkin received an M.A. degree in Science from Cambridge University, England, and an M.D. degree in Medicine from the Hebrew University of Jerusalem, Israel. He is the author of over 250 scientific publications and holds over 25 patents. Prof Belkin established and was the first full-time director of the Tel Aviv University Eye Research Institute. He was also

  • Head of the pediatric ophthalmology services at Hadassah University Hospital and Sheba Medical Center; 
  • Chairman of the Tel Aviv University Department of Ophthalmology;
  • President of the Israel Society of Eye and Vision Research of which he was a co-founder

Xinghuai SUN
Dr. SUN serves in Eye & ENT hospital since 1984 graduated from Shanghai Medical University and focus on glaucoma clinical and research work. He is the Chairman and professor, Department of Ophthalmology & Vision Science of Shanghai Medical College, Fudan University. He is also Chairman, Ophthalmology & Vision Science Committee of Chinese Research Hospital Association, President-elect of Chinese Ophthalmology Society, Vice Chairman of Chinese Glaucoma Society of Chinese Ophthalmology Society, and Vice President of Eye Doctor Association of China. Dr. SUN holds eight scientific projects from China national or ministerial research funding in the last 5 years.

Gerald M. Ostrov
From 2008 to 2010, Mr. Gerald M. Ostrov, also known as Jerry,served as Chairman and Chief Executive Officer of Bausch & Lomb Incorporated. From 1998 to 2006, Mr. Ostrov acted as Company Group Chairman for Johnson & Johnson's Worldwide Vision Care businesses. Mr. Ostrov began his career with Johnson & Johnson's Health Care Division in 1976. In 1982, he left Johnson & Johnson to become Vice President of Marketing for Ciba-Geigy's Consumer Pharmaceuticals Company, where he was named President of Ciba Consumer Pharmaceuticals in 1985 and served in that capacity until rejoining Johnson & Johnson in 1991 as President of the corporation's Personal Products Company. 

Gerd Auffarth
Professor and Chairman of The Department of Ophthalmology, Ruprecht-Karls University of Heidelberg, Director of the IVCRC and The David J Apple International Laboratory of Ocular Pathology at The University-Eye Clinic of Heidelberg, Germany. In addition to clinical and academic aspects, Dr. Gerd is also very active in the ophthalmic industry. In Ophthalmologist Power List 2018, Top 100 most influential people in the world of ophthalmology, Dr. Gerd ranks second in the world, which is also the highest ranking of European ophthalmologists.

TEAM,Rimonci睿盟希资本,

TEAM-Rimonci睿盟希资本

TEAM,Rimonci睿盟希资本